Replimune Group, Inc. (NASDAQ:REPL) Short Interest Down 16.5% in November

Replimune Group, Inc. (NASDAQ:REPL) was the recipient of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 5,580,000 shares, a decline of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily volume of 828,800 shares, the short-interest ratio is currently 6.7 days.

Insiders Place Their Bets

In related news, insider Konstantinos Xynos sold 7,246 shares of the firm’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.80% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. Quest Partners LLC boosted its holdings in shares of Replimune Group by 30.4% in the second quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after buying an additional 3,150 shares during the period. Algert Global LLC boosted its stake in Replimune Group by 5.4% in the 2nd quarter. Algert Global LLC now owns 84,033 shares of the company’s stock worth $756,000 after purchasing an additional 4,340 shares during the period. Creative Planning grew its position in Replimune Group by 28.7% during the 3rd quarter. Creative Planning now owns 21,047 shares of the company’s stock worth $231,000 after purchasing an additional 4,699 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after purchasing an additional 4,946 shares during the period. Finally, Los Angeles Capital Management LLC lifted its holdings in shares of Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Trading Up 2.7 %

Shares of NASDAQ:REPL opened at $12.55 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The stock has a market capitalization of $858.67 million, a price-to-earnings ratio of -4.11 and a beta of 1.26. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a 50 day moving average price of $12.19 and a 200 day moving average price of $10.45.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. On average, research analysts anticipate that Replimune Group will post -2.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, December 4th. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research note on Friday, November 22nd. Finally, Roth Mkm began coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $17.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.